Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Saif, Wasif M
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors	Recruiting	1/2	368	Europe, Canada, Japan, US, RoW	Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil	Takeda, Takeda Development Center Americas, Inc. (TDC Americas)	Solid Neoplasms	01/26	01/26
NCT05580770: Mirdametinib + BGB-3245 in Advanced Solid Tumors	Recruiting	1/2	136	US, RoW	Mirdametinib, PD-0325901, BGB-3245	SpringWorks Therapeutics, Inc.	Advanced Solid Tumor	10/26	06/27
NCT04659135: ASCO Survey on COVID-19 in Oncology (ASCO) Registry	Active, not recruiting	N/A	7000	US		American Society of Clinical Oncology	Neoplasms, Coronavirus	08/24	01/25